Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Faeth Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −10 vs. Q1 2025
- Shares held
- 69.9K
- −26.5K (−27.5%) vs. Q1 2025Converted for a 1-for-20 split
- Total value
- $600.0K
- −$160.2K (−21.1%) vs. Q1 2025
- New holders
- 0
- 4 more added
- Sold out
- 10
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 9 | $77 | 0.00% | +1+12.5% | AddedConverted for a 1-for-20 split |
| Morgan Stanley | 10 | $86 | 0.00% | −451−97.8% | ReducedConverted for a 1-for-20 split |
| JPMorgan Chase & Co | 32 | $275 | 0.00% | −3−8.8% | ReducedConverted for a 1-for-20 split |
| SBI Securities Co., Ltd. | 149 | $1.28K | 0.00% | +144+3,139.1% | AddedConverted for a 1-for-20 split |
| Bank of America Corp | 583 | $5.00K | 0.00% | +576+8,111.3% | AddedConverted for a 1-for-20 split |
| Raymond James Financial Inc | 700 | $6.01K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| UBS Group AG | 2,140 | $18.4K | 0.00% | +13+0.6% | AddedConverted for a 1-for-20 split |
| Catalio Capital Management, LP | 14,718 | $126.3K | 0.03% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Ikarian Capital, LLC | 22,497 | $193.0K | 0.06% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Vanguard Group Inc | 29,090 | $249.6K | 0.00% | −189−0.6% | ReducedConverted for a 1-for-20 split |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −8,865−100.0% | Sold outConverted for a 1-for-20 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −7,535−100.0% | Sold outConverted for a 1-for-20 split |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −5,433−100.0% | Sold outConverted for a 1-for-20 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −1,299−100.0% | Sold outConverted for a 1-for-20 split |
| State Street Corp | 0 | $0 | 0.00% | −1,289−100.0% | Sold outConverted for a 1-for-20 split |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −984−100.0% | Sold outConverted for a 1-for-20 split |
| NWF Advisory Services Inc. | 0 | $0 | 0.00% | −826−100.0% | Sold outConverted for a 1-for-20 split |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −270−100.0% | Sold outConverted for a 1-for-20 split |
| Barclays PLC | 0 | $0 | 0.00% | −128−100.0% | Sold outConverted for a 1-for-20 split |
| Citigroup Inc | 0 | $0 | 0.00% | −6−100.0% | Sold outConverted for a 1-for-20 split |